pharma · Pulmonary Arterial Hypertension (PAH)
AOP Orphan Pharmaceuticals
AOP Orphan Pharmaceuticals GmbH
AOP Orphan Pharmaceuticals is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension (PAH). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s),
Wien, AT HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- Wien, AT
- Programs
- 2
- Drugs
- 1
- Patents
- 7
TREPaed
Phase 3 · small molecule · Pulmonary Arterial Hypertension (PAH)
TREPaed for Pulmonary Arterial Hypertension (PAH) is a Phase 3 program (small_molecule) at AOP Orphan Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).
Internal code TREPaed
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AOP Orphan Pharmaceuticals GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pulmonary Arterial Hypertension (PAH)
- Status
- active
- Trials
- 1